Home > Dermatology > AAD 2020 > ECLIPSE trial: skin clearance independent of PsA status at baseline

ECLIPSE trial: skin clearance independent of PsA status at baseline

Patients with and without psoriatic arthritis (PsA) at baseline have a similar benefit from treatment with secukinumab and guselkumab at 48 weeks, as was demonstrated in a new analysis of the phase 3 ECLIPSE trial [1].

The ECLIPSE trial compared the anti-IL-23 monoclonal antibody guselkumab head-to-head with the IL-17A blocker secukinumab for the treatment of moderate-to-severe plaque psoriasis. The primary endpoint of the ECLIPSE trial was the proportion of patients achieving a Psoriasis Area and Severity Index (PASI) 90 at week 48. In the overall study population, a significantly greater proportion of patients in the guselkumab group achieved this primary endpoint compared with the secukinumab group. This result was published earlier this year [2].

In the current analysis, proportions of patients at week 48 achieving PASI 90, PASI 100, Investigator’s Global Assessment (IGA) score 0/1 (c...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on